Do analysts rate IMUX or INCR?

Immunic presently has a consensus target price of $47.57, indicating a potential upside of 214.31%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.00 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, IMUX or INCR?

InterCure has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A InterCure $78.47M 0.63 -$10.37M $0.03 30.17

Is IMUX or INCR more profitable?

InterCure's return on equity of 0.00% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% InterCure N/A N/A N/A

Do analysts rate KRRO or INCR?

Korro Bio presently has a consensus target price of $16.71, suggesting a potential upside of 42.37%. Given Korro Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Korro Bio is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 2.92 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, KRRO or INCR?

InterCure has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Korro Bio $6.39M 26.49 -$117.26M -$11.67 N/A InterCure $78.47M 0.63 -$10.37M $0.03 30.17

Is KRRO or INCR more profitable?

InterCure has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. InterCure's return on equity of 0.00% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -117.86% -71.04% InterCure N/A N/A N/A

Do analysts rate WHWK or INCR?

Whitehawk Therapeutics presently has a consensus price target of $8.20, indicating a potential upside of 115.22%. Given Whitehawk Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Whitehawk Therapeutics is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Whitehawk Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is WHWK or INCR more profitable?

InterCure's return on equity of 0.00% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -79.63% -74.01% InterCure N/A N/A N/A

Do analysts rate INCR or TNXP?

Tonix Pharmaceuticals has a consensus price target of $24.00, indicating a potential upside of 108.24%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tonix Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00

Do analysts prefer INCR or TNYA?

Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 380.19%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Is INCR or TNYA more profitable?

InterCure's return on equity of 0.00% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Tenaya Therapeutics N/A -80.56% -65.21%

InterCure (INCR) Competitors

$0.90 -0.01 (-0.55%)

As of 01:43 PM Eastern

Compare

INCR vs. IMUX, KRRO, WHWK, TNXP, and TNYA

Should you buy InterCure stock or one of its competitors? MarketBeat compares InterCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InterCure include Immunic (IMUX), Korro Bio (KRRO), Whitehawk Therapeutics (WHWK), Tonix Pharmaceuticals (TNXP), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry.

How does InterCure compare to Immunic?

Immunic (NASDAQ:IMUX) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

51.8% of Immunic shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 5.5% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Immunic's average media sentiment score of 0.00 equaled InterCure'saverage media sentiment score.

Company	Overall Sentiment
Immunic	Neutral
InterCure	Neutral

InterCure has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
InterCure	$78.47M	0.63	-$10.37M	$0.03	30.17

Immunic presently has a consensus target price of $47.57, indicating a potential upside of 214.31%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Immunic has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, InterCure has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

InterCure's return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
InterCure	N/A	N/A	N/A

Summary

InterCure beats Immunic on 7 of the 13 factors compared between the two stocks.

How does InterCure compare to Korro Bio?

Korro Bio (NASDAQ:KRRO) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

InterCure has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. InterCure's return on equity of 0.00% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
InterCure	N/A	N/A	N/A

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 4.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Korro Bio has a beta of 3, meaning that its stock price is 200% more volatile than the broader market. Comparatively, InterCure has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

InterCure has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	26.49	-$117.26M	-$11.67	N/A
InterCure	$78.47M	0.63	-$10.37M	$0.03	30.17

In the previous week, Korro Bio's average media sentiment score of 0.00 equaled InterCure'saverage media sentiment score.

Company	Overall Sentiment
Korro Bio	Neutral
InterCure	Neutral

Korro Bio presently has a consensus target price of $16.71, suggesting a potential upside of 42.37%. Given Korro Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Korro Bio is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Korro Bio beats InterCure on 8 of the 15 factors compared between the two stocks.

How does InterCure compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and InterCure (NASDAQ:INCR) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Whitehawk Therapeutics presently has a consensus price target of $8.20, indicating a potential upside of 115.22%. Given Whitehawk Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Whitehawk Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Whitehawk Therapeutics' average media sentiment score of 1.18 beat InterCure's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Whitehawk Therapeutics	Positive
InterCure	Neutral

Whitehawk Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, InterCure has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

InterCure has higher revenue and earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	26.39	-$20.60M	-$1.68	N/A
InterCure	$78.47M	0.63	-$10.37M	$0.03	30.17

InterCure's return on equity of 0.00% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
InterCure	N/A	N/A	N/A

Summary

Whitehawk Therapeutics and InterCure tied by winning 7 of the 14 factors compared between the two stocks.

How does InterCure compare to Tonix Pharmaceuticals?

InterCure (NASDAQ:INCR) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than InterCure. MarketBeat recorded 2 mentions for Tonix Pharmaceuticals and 0 mentions for InterCure. Tonix Pharmaceuticals' average media sentiment score of 0.17 beat InterCure's score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Tonix Pharmaceuticals	Neutral

InterCure has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.63	-$10.37M	$0.03	30.17
Tonix Pharmaceuticals	$13.11M	14.01	-$124.02M	-$14.36	N/A

8.3% of InterCure shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Tonix Pharmaceuticals has a consensus price target of $24.00, indicating a potential upside of 108.24%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

InterCure has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market.

InterCure has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. InterCure's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

Summary

Tonix Pharmaceuticals beats InterCure on 9 of the 16 factors compared between the two stocks.

How does InterCure compare to Tenaya Therapeutics?

InterCure (NASDAQ:INCR) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, Tenaya Therapeutics had 2 more articles in the media than InterCure. MarketBeat recorded 2 mentions for Tenaya Therapeutics and 0 mentions for InterCure. Tenaya Therapeutics' average media sentiment score of 0.26 beat InterCure's score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Tenaya Therapeutics	Neutral

8.3% of InterCure shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

InterCure's return on equity of 0.00% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 380.19%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

InterCure has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.63	-$10.37M	$0.03	30.17
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

InterCure has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.83, indicating that its share price is 183% more volatile than the broader market.

Summary

Tenaya Therapeutics beats InterCure on 9 of the 15 factors compared between the two stocks.

Get InterCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCR vs. The Competition

Export

Metric	InterCure	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$49.49M	$8.58B	$6.80B	$12.43B
Dividend Yield	N/A	2.48%	2.67%	9.39%
P/E Ratio	30.17	15.48	27.03	24.19
Price / Sales	0.63	6.83	515.69	92.93
Price / Cash	N/A	18.55	26.68	47.25
Price / Book	0.43	3.27	10.67	6.24
Net Income	-$10.37M	$230.22M	$3.59B	$331.42M
7 Day Performance	-8.59%	-1.58%	-0.60%	-1.18%
1 Month Performance	-2.55%	-1.81%	1.63%	-1.34%
1 Year Performance	-41.61%	-0.62%	25.09%	18.73%

InterCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCR InterCure	0.9339 of 5 stars	$0.91 -0.5%	N/A	-40.1%	$49.49M	$78.47M	30.17	350	Gap Up
IMUX Immunic	2.6583 of 5 stars	$14.77 -3.8%	$47.57 +222.1%	+55.6%	$209.23M	N/A	N/A	70
KRRO Korro Bio	2.0115 of 5 stars	$14.72 +1.6%	$16.71 +13.5%	-15.9%	$208.98M	$6.39M	N/A	70	Gap Up
WHWK Whitehawk Therapeutics	2.6848 of 5 stars	$3.96 -4.6%	$8.00 +102.0%	+110.6%	$205.23M	$7.14M	N/A	21
TNXP Tonix Pharmaceuticals	3.8517 of 5 stars	$12.78 +0.6%	$24.00 +87.8%	-76.6%	$202.61M	$13.11M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InterCure (INCR) Competitors

INCR vs. IMUX, KRRO, WHWK, TNXP, and TNYA

How does InterCure compare to Immunic?

Summary

How does InterCure compare to Korro Bio?

Summary

How does InterCure compare to Whitehawk Therapeutics?

Summary

How does InterCure compare to Tonix Pharmaceuticals?

Summary

How does InterCure compare to Tenaya Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InterCure (INCR) Competitors

INCR vs. IMUX, KRRO, WHWK, TNXP, and TNYA

How does InterCure compare to Immunic?

Do insiders & institutionals hold more shares of IMUX or INCR?

Does the media prefer IMUX or INCR?

Which has higher valuation and earnings, IMUX or INCR?

Do analysts rate IMUX or INCR?

Which has more risk and volatility, IMUX or INCR?

Is IMUX or INCR more profitable?

Summary

How does InterCure compare to Korro Bio?

Is KRRO or INCR more profitable?

Do institutionals & insiders have more ownership in KRRO or INCR?

Which has more risk & volatility, KRRO or INCR?

Which has stronger valuation and earnings, KRRO or INCR?

Does the media prefer KRRO or INCR?

Do analysts rate KRRO or INCR?

Summary

How does InterCure compare to Whitehawk Therapeutics?

Do analysts rate WHWK or INCR?

Does the media refer more to WHWK or INCR?

Which has more risk and volatility, WHWK or INCR?

Do institutionals and insiders believe in WHWK or INCR?

Which has preferable valuation and earnings, WHWK or INCR?

Is WHWK or INCR more profitable?

Summary

How does InterCure compare to Tonix Pharmaceuticals?

Does the media favor INCR or TNXP?

Which has higher earnings and valuation, INCR or TNXP?

Do institutionals and insiders hold more shares of INCR or TNXP?

Do analysts rate INCR or TNXP?

Which has more volatility and risk, INCR or TNXP?

Is INCR or TNXP more profitable?

Summary

How does InterCure compare to Tenaya Therapeutics?

Does the media prefer INCR or TNYA?

Do insiders & institutionals hold more shares of INCR or TNYA?

Is INCR or TNYA more profitable?

Do analysts prefer INCR or TNYA?

Which has preferable valuation & earnings, INCR or TNYA?

Which has more risk & volatility, INCR or TNYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools